<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093400</url>
  </required_header>
  <id_info>
    <org_study_id>21-006529</org_study_id>
    <nct_id>NCT05093400</nct_id>
  </id_info>
  <brief_title>Oropharynx (OPX) Salivary Biomarker Study</brief_title>
  <official_title>Oropharynx (OPX) Salivary Biomarker Study: Microbiome, Virome, and Metabolomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to analyze certain biomarkers to look at the relationship between&#xD;
      HPV in the saliva, stage at presentation, and a potential self-test compared to saliva of&#xD;
      non-cancerous participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Oncologic strains in HPV DNA salivary samples</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients to have oncologic strains of HPV DNA in salivary samples</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Normal Saliva</arm_group_label>
    <description>saliva from &quot;normal healthy&quot; adults.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>saliva collection</description>
    <arm_group_label>Normal Saliva</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, saliva, and tumor tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy non-cancerous participants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oropharynx or Oral Cavity Squamous Cell Carcinoma Patients: collected under the OPX&#xD;
             Biomarker Protocol (IRB: 19-006036).&#xD;
&#xD;
        Normal Controls:&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Able to provide informed written consent documenting permission to give saliva sample&#xD;
             for research testing.;&#xD;
&#xD;
          -  Ability to complete questionnaire(s) by themselves or with assistance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oropharynx or Oral Cavity Squamous Cell Carcinoma Patients: collected under the OPX&#xD;
             Biomarker Protocol (IRB: 19-006036).&#xD;
&#xD;
        Normal Controls:&#xD;
&#xD;
          -  Any personal history of head or neck cancer including head or neck skin cancer.&#xD;
&#xD;
          -  Other active malignancy ≤ 5 years prior to registration.&#xD;
&#xD;
          -  EXCEPTIONS: Non-melanotic skin cancer, non-metastatic prostate cancer.&#xD;
&#xD;
          -  NOTE: If there is a history of prior malignancy, they must not be receiving other&#xD;
             specific treatment for their cancer.&#xD;
&#xD;
          -  Dry mouth (xerostomia) caused by any chronic (&gt;30 days) condition (known or unknown)&#xD;
             or medication.&#xD;
&#xD;
          -  Recent (within 30 days) or active upper aerodigestive tract or anogenital infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Van Abel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Tuchscherer</last_name>
      <phone>507-538-6582</phone>
      <email>Tuchscherer.Amy@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kathryn (Katie) M. Van Abel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

